Regeneron Pharmaceuticals will make its newly approved gene therapy for a rare form of hearing loss, Otarmeni, available for free in the US. The company has not yet decided on the cost of the therapy in other countries. This move is part of a larger agreement with the Trump administration regarding drug pricing, which has been argued that Americans are unfairly paying more for drugs than other wealthy nations. The treatment was approved under the Food and Drug Administration's National Priority Voucher program.